Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05238025 · ClinicalTrials.gov registry record · Phase 3
MVA-BN-RSV Vaccine Trial
A Phase 3 study, sponsored by Bavarian Nordic.
- Terminated
- Registry status
- Phase 3
- Development phase
- 20,419
- Enrollment target
NCT05238025: Clinical Trial Phase 3 study, sponsored by Bavarian Nordic.
NCT05238025 is a Phase 3 study that was terminated before completion, run by Bavarian Nordic. The registered enrollment target is 20,419 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2548% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05238025, a Phase 3 study, was terminated before completion, sponsored by Bavarian Nordic.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 20,419 participants
- Enrollment target
Study Summary
Phase 3 randomized, double blind study comparing recombinant MVA-BN-RSV vaccine vs placebo for efficacy and safety in adults \>=60 years of age
Primary Outcome
RSV-associated lower respiratory tract disease (LRTD) is defined by the presence of clinical evidence of at least 1 sign or symptom of acute respiratory disease (ARD) and at least 3 LRTD signs or symptoms with onset ≥14 days following vaccination until the end of one RSV season (up to 12 months after vaccination), confirmed and documented by a medical professional, together with RSV disease confirmed by polymerase chain reaction (PCR)
Interventions
- BIOLOGICAL MVA-BN-RSV vaccine
- BIOLOGICAL Tris Buffered Saline (TBS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,419 participants |
| Start Date | 2022-04-19 |
| Est. Completion | 2023-09-01 |
| Phase | Phase 3 |
Why NCT05238025 stopped before completion
NCT05238025 is an interventional study that assigns participants to a tested intervention. Its 20,419 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2548% higher).
The record links to 0 conditions, and to 2 interventions - of which MVA-BN-RSV vaccine is the first listed.
NCT05238025 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05238025 about?
NCT05238025 is a clinical study titled "MVA-BN-RSV Vaccine Trial". Phase 3 randomized, double blind study comparing recombinant MVA-BN-RSV vaccine vs placebo for efficacy and safety in adults \>=60 years of age
What is the current status of trial NCT05238025?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 20,419 participants. The study started on 2022-04-19. Estimated completion is 2023-09-01.
What interventions are being tested in trial NCT05238025?
The interventions under investigation include: MVA-BN-RSV vaccine (BIOLOGICAL), Tris Buffered Saline (TBS) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05238025?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05238025's enrollment target sits among peer trials
20,419 9th of 2000 higher than 1,992 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06062342 · 20,400 participants · NA
Five Point Initiative: A Bundled Implementation Strategy to Address the HIV Epidemic in Black Communities
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
- NCT00900471 · 20,000 participants
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI